Download Files:
NHWD-870
$470 – $4,090
Products Details
Product Description
– NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction. NHWD-870 increases tumor apoptosis and inhibits tumor proliferation[1].
Web ID
– HY-134463
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H29N7O
References
– [1]Yin M, et al. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun. 2020;11(1):1833. Published 2020 Apr 14.|[2]Nenghui Wang, et al. Abstract 1382: A novel BET family bromodomain inhibitor NHWD-870 represents a promising therapeutic agent for a broad spectrum of cancers. Molecular and Cellular Biology, Genetics.
CAS Number
– 2115742-03-3
Molecular Weight
– 491.59
Compound Purity
– 99.36
SMILES
– CN1N=CC2=CC3=C(N([C@H](C4=CC=CC=C4)C5CCOCC5)C6=CC(C7=C(C)N=NN7C)=CN=C63)C=C12
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Apoptosis;Epigenetic Reader Domain
Pathway
– Apoptosis;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
